Therefore, neither BAX nor TP53 mutations contributed to acquired DLBCL venetoclax resistance in the DLBCL lines, but a BH3-binding domain mutation in BCL2 in SUDHL4 cells did. Here, BAX is linked to diffuse large B-cell lymphoma.